<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343276">
  <stage>Registered</stage>
  <submitdate>8/08/2011</submitdate>
  <approvaldate>15/08/2011</approvaldate>
  <actrnumber>ACTRN12611000865910</actrnumber>
  <trial_identification>
    <studytitle>A Phase III Randomised, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Tranexamic Acid in Reducing the Blood Loss in Patients with Per-rectal Bleeding</studytitle>
    <scientifictitle>A Phase III Randomised, Double-blind, Placebo-controlled Pragmatic Trial to Assess the Efficacy of Tranexamic Acid in Reducing the Blood Loss in Patients with Per-rectal Bleeding</scientifictitle>
    <utrn />
    <trialacronym>TRAPR Study</trialacronym>
    <secondaryid>Clinical Trial Procotol Number JHHGIS01</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>lower gastrointestinal bleeding</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Tranexamic acid 1000mg taken orally every 6 hours for 4 days.</interventions>
    <comparator>Placebo capsule, consisting of rice flour-based capsule, taken orally every 6 hours for four days.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood loss as assessed by reduction in haemoglobin concentration.</outcome>
      <timepoint>Day 1, 2, 3, 4 and day of discharge</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Number of units of packed red blood cells administered to participants according to the clinical record</outcome>
      <timepoint>At time of discharge</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Written informed consent
Per rectum bleeding
Able to swallow study medications</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects less than 18 years
Patients with dementia or other health conditions that prevent a person from giving written informed consent.
History of thromboembolic disease or family history of same.
Subjects taking warfarin.
Subjects that are within 12 months of insertion of a drug-eluting stent.
Subjects that are within 12 weeks of placement of a bare metal stent.
Subjects that are pregnant and/or breastfeeding.
Subjects with a known gastrointestinal malignancy
Subjects with a known cancer in the palliative care phase of their treatment.
Subjects with a known allergy to tranexamic acid or its excipients.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After a potential partiticipant has met all eligibility criteria and written informed consent has been obtained, the researcher will randomise the patient by central randomisation by computer.</concealment>
    <sequence>Permuted block randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/11/2011</anticipatedstartdate>
    <actualstartdate>9/11/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>7/01/2014</actualenddate>
    <samplesize>100</samplesize>
    <actualsamplesize>100</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>John Hunter Hospital Royal Newcastle Centre - New Lambton</hospital>
    <postcode>2305 - New Lambton Heights</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>John Hunter Hospital</primarysponsorname>
    <primarysponsoraddress>Lookout Road 
New Lambton Heights NSW 2305</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>John Hunter Hospital</fundingname>
      <fundingaddress>Lookout Road 
New Lambton Heights NSW 2305</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A study to assess the effectiveness of oral tranexamic acid to placebo in reducing the amount of blood loss from lower gastrointestinal bleeding, and to reduce the amount of blood needed to be transfused.</summary>
    <trialwebsite />
    <publication>DOES TRANEXAMIC ACID REDUCE BLOOD LOSS IN PER RECTAL BLEEDING? (TRAPR STUDY)
David Murray, Stephen Smith, Brian Draganic, Peter Pockney, Rosemary Carroll and John Attia
ANZ Journal of Surgery
Special Issue: Abstracts of the RACS Annual Scientific Congress and ANZCA Annual Scientific Meeting, Singapore, 59 May 2014
Volume 84, Issue Supplement S1, pages 3052, May 2014

</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Locked Bag 1
New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>1/08/2011</ethicapprovaldate>
      <hrec>11/07/20/3.06</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Stephen Smith</name>
      <address>Division of Surgery
John Hunter Hospital
Locked Bag 1
Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 49855153</phone>
      <fax />
      <email>stephen.smith@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Rosemary Carroll</name>
      <address>Division of Surgery
John Hunter Hospital
Locked Bag 1
Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 49855153</phone>
      <fax>+61 2 49214274</fax>
      <email>rosemary.carroll@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rosemary Carroll</name>
      <address>Division of Surgery
John Hunter Hospital
Locked Bag 1
Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 49855153</phone>
      <fax>+61 2 49214274</fax>
      <email>rosemary.carroll@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Stephen Smith</name>
      <address>Division of Surgery
John Hunter Hospital
Locked Bag 1 
Hunter Region Mail Centre NSW 2310</address>
      <phone>+61 2 49855568</phone>
      <fax />
      <email>stephen.smith@hnehealth.nsw.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>